DP
TVRD

Diadema Partners’s Tvardi Therapeutics TVRD Stock Holding History

Diadema Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.6K Buy
+16,607
New +$52.1K ﹤0.01% 142
2025
Q4 		– Sell
-2,185
Closed -$85.1K – 201
2025
Q3 		$85.1K Buy
+2,185
New +$62.2K 0.02% 121

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Diadema Partners's TVRD Position: Q2 2026 in Review

Diadema Partners opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 16,607 shares worth $31.6K. The stake represents ﹤0.01% of the portfolio and ranks #142 among its holdings. This is a return to the name: Diadema Partners previously reported a position in TVRD as recently as Q3 2025.

Diadema Partners first reported a position in TVRD in Q3 2025 and has held it in 2 quarters since. The position peaked at $85.1K in Q3 2025. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Diadema Partners held 16,607 shares of Tvardi Therapeutics worth $31.6K as of Q2 2026.
  • Tvardi Therapeutics was a new Diadema Partners position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Diadema Partners's portfolio in Q2 2026, its #142 holding.
  • Diadema Partners first reported a position in Tvardi Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Diadema Partners's Tvardi Therapeutics position peaked at $85.1K in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.